¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á CDMO ½ÃÀå º¸°í¼­(2025³â)
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025
»óǰÄÚµå : 1825653
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á CDMO ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºñ¾àÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 26.2%·Î 175¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Ä¡·á ¿ëµµ È®´ë, ±ÔÁ¦ ÁøÈ­, ÅõÀÚ Áõ°¡, ±â¼ú Çõ½Å, ¼¼°è Çù·Â °ü°è µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÚµ¿È­ ¹× µðÁöÅÐÈ­ ¹ßÀü, Á¦Á¶ ´É·Â È®´ë, »õ·Î¿î Àü´Þ ½Ã½ºÅÛÀÇ µîÀå, Áö¼Ó°¡´É¼º ¹× ȯ°æ ¿µÇâ¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ 26.2%ÀÇ ¼ºÀå·ü Àü¸ÁÀº Áö³­¹ø Àü¸ÁÄ¡º¸´Ù 0.6% ¼ÒÆø Ç϶ôÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ¿¡ ±âÀÎÇÕ´Ï´Ù. ¹«¿ª ¸¶ÂûÀº ¾ÆÀÏ·£µå¿Í µ§¸¶Å©¿¡¼­ °³¹ßµÈ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ¿Í ¹ÐÆóÇü ó¸® ½Ã½ºÅÛÀÇ °¡°ÝÀ» »ó½Â½Ã۰í, Á¦Á¶ÀÇ º´¸ñÇö»óÀ» ÀÏÀ¸ÄÑ Ã·´Ü Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚ Á¢±ÙÀ» Áö¿¬½ÃÅ´À¸·Î½á ¹Ì±¹ÀÇ »ý¸í°øÇÐ Çõ½ÅÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »óÈ£ °ü¼¼¿Í ¹«¿ª ±äÀå°ú Á¦ÇÑ Áõ°¡·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀº ´õ¿í ±¤¹üÀ§ÇÏ°Ô ³ªÅ¸³¯ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾Ï ȯÀÚ À¯º´·ü Áõ°¡´Â ¼¼Æ÷-À¯ÀüÀÚÄ¡·áÁ¦ ¼öʰ³¹ß»ý»ê(CDMO) ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ ÅëÁ¦ÇÒ ¼ö ¾ø´Â Áõ½Ä°ú È®»êÀ» Ư¡À¸·Î ÇÏ´Â ¾ÏÀº Àα¸ÀÇ °í·ÉÈ­, »ýȰ½À°üÀÇ º¯È­, ȯ°æ ³ëÃâ, °ËÃâ ¹æ¹ýÀÇ °³¼± µîÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. CDMO´Â È¿´É°ú ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â Çõ½ÅÀûÀΠǥÀû Ä¡·áÁ¦¸¦ °³¹ß ¹× Á¦Á¶ÇÔÀ¸·Î½á ¾Ï ÅðÄ¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿µ±¹¿¡ ±â¹ÝÀ» µÐ ÀÚ¼±´ÜüÀÎ ¸Æ¹Ð·± ¾Ï Áö¿ø(Macmillan Cancer Support)¿¡ µû¸£¸é, ¿µ±¹¿¡¼­ ¾ÏÀ» ¾Î°í ÀÖ´Â »ç¶÷ÀÇ ¼ö´Â 2022³â 300¸¸ ¸í¿¡¼­ 2025³â 350¸¸ ¸í, 2030³â 400¸¸ ¸í, 2030³â 530¸¸ ¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ±× °á°ú, ¾Ï ȯÀÚ Áõ°¡°¡ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á CDMO ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í ÄڷγªÀç³­°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that supports the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations provide services tailored to the specific needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs are crucial in speeding up the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services from early-stage development through to commercialization.

The primary product types offered by cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person's cells to treat or prevent disease. These therapies undergo various phases, including phase 1, phase 2, phase 3, and phase 4, and are developed for a range of indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell and gene therapy contract development and manufacturing organization (CDMO) market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy contract development and manufacturing organization (CDMO) market statistics, including cell and gene therapy contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (CDMO) market share, detailed cell and gene therapy contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (CDMO) industry. This cell and gene therapy contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size has grown exponentially in recent years. It will grow from $5.41 billion in 2024 to $6.92 billion in 2025 at a compound annual growth rate (CAGR) of 27.9%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is expected to see exponential growth in the next few years. It will grow to $17.57 billion in 2029 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.

The forecast of 26.2% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. biotech innovation by inflating prices of single-use bioreactors and closed processing systems developed in Ireland and Denmark, resulting in manufacturing bottlenecks that delay patient access to cutting-edge treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer cases is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, characterized by uncontrolled growth and spread of abnormal cells, is becoming more common due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. CDMOs play a crucial role in combating cancer by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. For example, according to Macmillan Cancer Support, a UK-based charitable organization, the number of people living with cancer in the UK is projected to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing prevalence of cancer cases is fueling the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating on broadening their portfolio by integrating advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system designed for large-scale production of cell-based products. This innovative technology enables 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a new business division providing cell therapy manufacturing services as a CDMO. This new division encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division delivers end-to-end services ranging from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as outlined in a company announcement. It harnesses the company's state-of-the-art PluriMatrix technology to provide advanced cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based company specializing in food and biotechnology, purchased Forge Biologics for $620 million. This acquisition enhances Ajinomoto's worldwide expertise in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, strengthening its current contract development and manufacturing services. Forge Biologics, based in the US, is a contract development and manufacturing organization (CDMO) for gene therapy and a clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell and gene therapy contract development and manufacturing organization (cdmo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell and gene therapy contract development and manufacturing organization (cdmo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Characteristics

3. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies

4. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Growth Analysis And Strategic Analysis Framework

6. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segmentation

7. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Regional And Country Analysis

8. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

9. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

10. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

11. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

12. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

13. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

14. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

15. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

16. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

17. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

18. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

19. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

20. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

21. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

22. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

23. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

24. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

25. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

26. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

27. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

28. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

29. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

30. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape And Company Profiles

31. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Other Major And Innovative Companies

32. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

34. Recent Developments In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

35. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â